Preclinical Evaluation of18F-JNJ64349311, a Novel PET Tracer for Tau Imaging
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
In this study, we have synthesized and evaluated 18F-JNJ64349311, a tracer with high affinity for aggregated tau (inhibition constant value, 8 nM) and high (≥500×) in vitro selectivity for tau over β-amyloid, in comparison with the benchmark compound 18F-AV1451 (18F-T807) in mice, rats, and a rhesus monkey. Methods: In vitro binding characteristics were determined for Alzheimer9s disease, progressive supranuclear palsy, and corticobasal degeneration patient brain tissue slices using autoradiography studies. Ex vivo biodistribution studies were performed in mice. Radiometabolites were quantified in the brain and plasma of mice and in the plasma of a rhesus monkey using high-performance liquid chromatography. Dynamic small-animal PET studies were performed in rats and a rhesus monkey to evaluate tracer pharmacokinetics in the brain. Results: Mouse biodistribution studies showed moderate initial brain uptake and rapid brain washout. Radiometabolite analyses after injection of 18F-JNJ64349311 in mice showed the presence of a polar radiometabolite in plasma, but not in the brain. Semiquantitative autoradiography studies on postmortem tissue sections of human Alzheimer9s disease brains showed highly displaceable binding to tau-rich regions. No specific binding was, however, found on human progressive supranuclear palsy and corticobasal degeneration brain slices. Small-animal PET scans of Wistar rats revealed moderate initial brain uptake (SUV, ∼1.5 at 1 min after injection) and rapid brain washout. Gradual bone uptake was, however, also observed. Blocking and displacement did not affect brain time–activity curves, suggesting no off-target specific binding of the tracer in the healthy rat brain. A small-animal PET scan of a rhesus monkey revealed moderate initial brain uptake (SUV, 1.9 at 1 min after injection) with a rapid washout. In the monkey, no bone uptake was detected during the 120-min scan. Conclusion: This biologic evaluation suggests that 18F-JNJ64349311 is a promising tau PET tracer candidate, with a favorable pharmacokinetic profile, as compared with 18F-AV1451.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“timately failed in late-stage-development clinical trials (1).”
Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605 · cited 1×
“Air-dried frozen, 10-mm-thick postmortem slices of an AD patient (visual cortex of a 68-y-old woman with Braak stage VI), PSP patient (frontal cortex of a 71-y-old woman), and CBD patient (frontal cortex of a 74-y-old woman) were incubated for 60 min in a solution of tracer (740 kBq/500 mL per section) and subsequentl…”
MethodAn autoradiographic evaluation of AV-1451 Tau PET in dementia
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0315-6 · Cited by 474
Schwarz, A. J., Yu, P., Miller, B. B., Shcherbinin, S., Dickson, J., Navitsky, M., Joshi, A. D., Devous, M. D., & Mintun, M. S. (2016) · Brain · doi:10.1093/brain/aww023 · Cited by 425 · cited 1×
“This tracer is the most widely studied, and the signal in the brain has been demonstrated to follow Braak stages in cross-sectional studies of subjects at risk for AD to full blown AD (6).”
BackgroundVan den Bergh, A., Sinha, V., Gilissen, R., Straetemans, R., Wuyts, K., Morrison, D., Bijnens, L., & Mackie, C. (2011) · Clinical Pharmacokinetics · doi:10.2165/11587230-000000000-00000 · Cited by 33
Cited by
Tau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L., & Rowe, C. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.9 · Cited by 441
Pontecorvo, M. J., Devous, M. D., Kennedy, I., Navitsky, M., Lu, M., Galante, N., Salloway, S., Doraiswamy, P. M., Southekal, S., Arora, A. K., et al. (2019) · Brain · doi:10.1093/brain/awz090 · Cited by 249
Tau PET Imaging in Neurodegenerative Disorders
Groot, C., Villeneuve, S., Smith, R., Hansson, O., & Ossenkoppele, R. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263196 · Cited by 137
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
“Preliminary studies for these newer tracers have shown promising results (Declercq et al., 2017; Kuwabara et al., 2018; Guehl et al., 2019; Rombouts et al., 2019; Teng et al., 2019; Schmidt et al., 2020).”
Background
Metadata
- Authors
- Declercq, L., Rombouts, F., Koole, M., Fierens, K., Mariën, J., Langlois, X., Andrés, J. I., Schmidt, M., Macdonald, G., Moechars, D., Vanduffel, W., Tousseyn, T., Vandenberghe, R., Van Laere, K., Verbruggen, A., & Bormans, G.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2017-02-23
- Volume
- 58
- Issue
- 6
- Pages
- 975-981
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2590496942
- Cited by
- 83
- References
- 8
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical Evaluation of18F-JNJ64349311, a Novel PET Tracer for Tau Imaging. https://app.cochat.ai/papers/10.2967/jnumed.116.185199
- The paper
- Declercq, L., Rombouts, F., Koole, M., Fierens, K., Mariën, J., Langlois, X., Andrés, J. I., Schmidt, M., Macdonald, G., Moechars, D., Vanduffel, W., Tousseyn, T., Vandenberghe, R., Van Laere, K., Verbruggen, A., & Bormans, G. (2017). Preclinical Evaluation of18F-JNJ64349311, a Novel PET Tracer for Tau Imaging. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.116.185199
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.